<DOC>
	<DOCNO>NCT02734862</DOCNO>
	<brief_summary>The purpose study determine intravenous CD101 safe effective treatment candidemia compare caspofungin ( followed oral fluconazole ) .</brief_summary>
	<brief_title>STRIVE : CD101 Compared Caspofungin Followed Oral Step Down Treatment Subjects With Candidemia</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Fungemia</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>mycological diagnosis candidemia ( least 1 blood culture positive Candida positive test Candida sponsor approve rapid diagnostic test ) life expectancy great 72 hour female subject child bear potential &lt; 2 year post menopausal must agree one barrier method one highly effective method birth control sexual abstinence . male subject must agree use one barrier method birth control sexual abstinence provide inform consent presence one systemic sign attributable candidemia document suspected invasive candidiasis include intraabdominal infection , endocarditis , osteomyelitis , meningitis , endophthalmitis neutropenia alanine aminotransferase aspartate aminotransferase level &gt; 10 fold upper limit normal severe hepatic impairment subject history chronic cirrhosis great 48 hour systemic antifungal treatment approve dos treat candidemia pregnant lactating female nurse know hypersensitivity CD101 , caspofungin , echinocandin , excipients previous participation previous CD101 study recent use investigational medicinal product within 28 day first dose study drug presence investigational device time screen Principal Investigator considers subject participate presence indwell vascular catheter device remove likely source candidemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mycoses</keyword>
</DOC>